Scientific Interests

A few important International Original Articles in Lead Areas of work

a) Augmenting Chemotherapy toxicity & enhancing Supportive care in randomized fashion

1. Bajpai J, Kapu V, Rath S et al, Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial. The Lancet Oncology, Volume 25, Issue 2, 2024, Pages 246-254, ISSN 1470-2045, https://doi.org/10.1016/S1470-2045(23)00628-9.
2. Bajpai J et.al."Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia". Breast. 2019 Dec 12; 49:187-193. doi: 1016/j.breast.2019.12.004.

b) Epidemiology:

1. Mailankody S, Bajpai J (corresponding) et al. Epidemiology of rare cancers in India and South Asian countries-remembering the forgotten. The Lancet Regional Health Southeast Asia 2023 https://doi.org/10.1016/j.lansea.2023.100168

c) Work force disparity in oncology

1. Linardou H, Adjei AA, Bajpai J et al. Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey. https://doi.org/10.1016/j.esmoop.2023.100781
2. Bajpai J et.al. Gender climate in Indian oncology: national survey report Esmoopen-April 2020;5(2): e000671; DOI: 10.1136/esmoopen-2020-000671
3. Garrido P, Adjei AA, Bajpai J et al. Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. ESMO Open.Vol6;issue3.https://doi.org/10.1016/j.esmoop.2021.100131
4. Linardou H, Adjei A, Bajpai Jet al. Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey. esmoopen-2022-002881.R1 (in press).

d) Breast 

1. Lambertini M, Blondeaux E, Agostinetto E,….Bajpai J et al. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study. JAMA. 2024;331(1):49-59. doi:10.1001/jama.2023.25463
2. Bajpai Jal."Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia". Breast. 2019 Dec 12; 49:187-193. doi: 10.1016/j.breast.2019.12.004.
3. Bajpai J et.al. Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort. . . Breast. 2022;63:77-84. doi:10.1016/j.breast.2022.03.011
4. Bajpai J. et.al. Pregnancy-associated breast cancer (PABC): Demographics and outcome analysis from a lower and middle income country (LMIC). Annals of Oncology (2020) 31 (suppl_2): S54-S57. 10.1016/annonc/annonc120.
5. Bajpai J. et.al. Unique challenges and outcomes of young breast cancers from a tertiary care cancer centre in India. Annals of Oncology 32: S90 10.1016/j.annonc.2021.03.176
6. Mailankody S, Bajpai J(co-first and corresponding author) et al. Oncofertility and Pregnancy in Adolescent and Young Adult Cancers: Physicians' Knowledge and Preferences in India. JCO Glob Oncol. 2024;10:e2300205. doi:10.1200/GO.23.00205
7. Rath S, Elamarthi P, Parab P… J et al. (2021) Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice. PLoS ONE 16(7): e0253722. https://doi.org/10.1371/journal.pone.0253722
8. BajpaiJ et al. Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort. https://doi.org/10.1016/j.breast.2022.03.011
9. Jain M, Gupte S, Patil S...Bajpai J et al.Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study  Breast Cancer Res Treat 156:125–134
10. Bajpai J, RamaswamyA., GhoshJ., GuliaS.,GuptaS., Everolimus in heavily pre-treated metastatic breast cancer (MBC): Is real (developing) world experience different? September 2015 Volume 51, Supplement 3, Page S292. Europian Journal of cancer
11. Pivot X,Bajpai J, Aphase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results. Study Investigators per Country: India: Journal Clinical Oncology 2018 Feb 12; 93:19-27. doi: 10.1016/j.ejca.2018.01.072.
12. Bajpai J, Shylasree T.S. Sexual quality of life in breast and ovarian cancer survivors: Tip of the iceberg! a Department of Medical Oncology, 1115, 11th Floor, Journal of Cancer Policy 2018, https://doi.org/10.1016/j.jcpo.2018.02.002
13. Bajpai J and Shylasree T: Pregnancy‑associated breast cancer: Controversies and consensus! Oncobiology and Targets, 10.4103/2395-4469.192739
14. Ghosh J, Bajpai J (corresponding author) Hormone Therapy in Breast Cancer: Where do We Stand? J Integr Oncol 2017. 6: 184. doi:10.4172/2329-6771.1000184
15. Wadasadawala T, Swain M, Bajpai J. (corresponding author). Phyllodes tumor of the breast: Wolf inside the sheep’s skin! Oncobiol Targets 2016; 3:10.
16. Bajpai J, Ramaswamy A, Gupta S et al. Eribulin in heavily pretreated metastatic breastcancer: A tertiary care center experience from India. Indian Journal of Cancer 2016; 53:460-3.
17. Bajpai J, Susan D, Patil V, et al. Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in Indian J Med Paediatr Oncol. 2017;38(1):18-21. doi:10.4103/0971-5851.203498
18. Bajpai J, Ramaswamy A., et.al; Activation of phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway and response to everolimus in endocrine receptor‑positive metastatic breast cancer – A retrospective pilot analysis and viewpoint; South Asian J Cancer 2017; 06(03): 102-105 DOI: 10.4103/sajc.sajc_113_17
19. Bajpai J (corresponding author), Ramaswamy A, Gupta S, et.al. Everolimus in heavily pre-treated metastatic breast cancer: Is real world experience different? Indian Journal of Cancer 2016; 53:464-7.
20. Bajpai J, Majumdar A, Satwik R, Rohatgi N, Jain V, Gupta D, Agarwal R, Mittal S, Verma SK, Parikh PM, Aggarwal S, Practical consensus recommendations on fertility preservation in patients with breast cancer DOI: 10.4103/sajc.sajc_113_18
21. Bajpai J, Bharat C., Ravi T., Subhash R.K., Asawari P., Sudeep G. Billiary obstruction in a metastatic tumor of the pancreas from breast cancer. South Asian J Cancer 2017; 6:10-9.
22. Singh G, Bajpai J(Corresponding author) et al. Excellent response to erlotinib in breast carcinoma with rare EGFR mutation—a case report. E cancer 2020, 14:1092 ;www.ecancer.org; DOI: https://doi.org/10.3332/ecancer.2020.1092

e) Sarcomas

1. Bajpai Jal. Outcomes in non-metastatic extremity osteosarcoma patients treated with a novel non-high dose methotrexate based dose dense combination chemotherapy regimen “OGS-12”. Eur J Cancer. 2017 Nov; 85:49-58.
2. Bajpai J et.al. Osteosarcoma journey over two decades in India: Small steps, big changes; Pediatr Blood Cancer. 2019; e27877. https://doi.org/10.1002/pbc.27877
3. Bajpai J et.al. Outcomes in Treatment-Naïve Patients with Metastatic Extremity Osteosarcoma Treated with OGS-12, a Novel Non–High-Dose Methotrexate–Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center; Journal of Global Oncology.2018. (4):1-10.
4. Pandaet G. al (Bajpai J –corresponding author). Outcomes of Ewing sarcoma in adults over 40 years of age from a low-middle income country.https://doi.org/10.3332/ecancer.2022.1361.
5. Sekharan V., RamanathanS., ChinnaswamyG. … Bajpai J.,et.al. High Response Rates and Promising Outcomes of Patients with Relapsed Ewing Sarcoma, Especially in Adolescents and Young Adults Treated on a Novel Hybrid Salvage Chemotherapy Regimen; Journal of Adolescent and Young Adult Oncology VOL. 10, No. 2; 15 Apr 2021 https://doi.org/10.1089/jayao.2020.0016.
6. Bajpai J., Gamnagatti S., Kumar R. et al. Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis. Pediatr Radiol 41, 441–450 (2011). https://doi.org/10.1007/s00247-010-1876-3
7. Bajpai J., Panda G. S.,Chandrasekharan A., et.al. Adolescent–adult nonmetastatic Ewing sarcoma—Experience from a large developing country; Paediatric Blood and Cancer Journal; Volume68, Issue9, September 2021, e29081; 15 May 2021; https://doi.org/10.1002/pbc.29081.
8. Bajpai Jal. Chemotherapy compliance in patients with osteosarcoma. Pediatric Blood Cancer.2013Jan; 60(1):41-4.
9. Bajpai J al. "Prediction of Chemotherapy Response by PET-CT in Osteosarcoma: Correlation with Histologic Necrosis”.Journal of Pediatric Hematology/Oncology: 2011; 33 (7) e271–e278
10. Bajpai Jal. VEGF Expression as a Prognostic Marker in Osteosarcoma. Pediatric Blood Cancer 2009; 53:1035–1039
11. Bajpai J al. Non Invasive Imaging Surrogate of Angiogenesis in Osteosarcoma.Pediatric Blood Cancer 2010;54:526–531
12. Bajpai J. et.al. Multimodality, aggressive and sustainable care in metastatic osteosarcoma: A tertiary care cancer experience from India. Annals of Oncology, Volume 29, Issue suppl_9, 1 November 2018, y443, https://doi.org/10.1093/annonc/mdy443.ESMO Asia 2018
13. Bajpai J. et.al. Can fairer sex, febrile neutropenia & compliance influence surviving 5probability in non-metastatic osteosarcoma: Experience over two decades from India”. Annals of Oncology,002,https://doi.org/10.1093/annonc/mdy443.002. ESMO Asia 2018
14. Bajpai J. et al. “Evolution of Novel, Low Cost, Sustainable Osteosarcoma Care over Two Decades: Reducing Inefficiencies, & Improving Outcomes. Annals of Oncology 1 October 2018. Volume 29, Issue suppl_8, mdy299.031, https://doi.org/10.1093/annonc/mdy299.031
15. Bajpai J., ChandrakanthM.V,, et.al; Is non-HD–MTX based, dose-dense, combination chemotherapy a valid choice in osteosarcoma in developing world? Journal of Clinical Oncology 2014 32:15_suppl, 10537-10537
16. Malinkode S et al (Bajpai J –corresponding author).Resource-appropriate selection of osteosarcoma treatment protocols in low- and middle-income countries.^.Pediatr Blood Cancer. 2022 Mar;69(3):e29540. doi: 10.1002/pbc.29540. Epub 2021 Dec 31.
17. Bajpai J, Jaffe N. Perspectives of the Role of Chemotherapy in the Management of Osteosarcoma. Journal of Cancer Therapy .2012, 3,1911-1203 http://dx.doi.org/10.4236/jct.2012.36154
18. Bajpai J, et.al. Targeted Therapy of Soft Tissue Sarcoma: There is More than one Way to Skin a Cat! Chemo Open Access 5: 216. doi:10.4172/2167-7700.1000216
19. Chandrakanth MV, Bajpai J. (corresponding author)Compliance to Therapy as a Prognostic Marker in Osteosarcoma: New Kid on the Block! DiagnPathol Open 1:119.
20. Sharda M, Bajpai J et.al.(corresponding author). Widely Disseminated Metastatic Ewing sarcoma: Sustained, Complete Metabolic Response to First-Line Oral Metronomic Chemotherapy.PBC-20-0460
21. Bajpai J, Sujeeth M, Kappor A etal.Indian J Cancer.Pazopanib in metastatic soft tissue sarcomas: Testing the waters in developing world. . Jul-Sep 2021;58(3):365-370. doi: 10.4103/ijc. Indian J Cancer IJC_314_19
22. Bajpai J, Khanna N, Vora T et.al. Analysis of bone and soft‑tissue sarcomas registered during the year 2012 at Tata Memorial Hospital, Mumbai, with clinical outcomes. Indian Journal of Cancer 2018; 10.4103/ijc. Indian J CancerIJC_481_17
23. Bajpai J, Mullapally SK, Kapoor A, et.al. Pazopanib in metastatic soft tissue sarcomas: Testing the waters in developing world. Indian J Cancer [serial online] 2021 [cited 2021 Sep 27]; 58:365-70.
24. Bajpai J., Deepa S. (2015) Role of Systemic Therapy in the Management of Uterine Sarcomas. In: Rajaram S., K C., Maheshwari A. (eds) Uterine Cancer. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1892-0_33
25. Bajpai J., Deepa S. (2015) Role of Systemic Therapy in the Management of Uterine Sarcomas. In: Rajaram S., K C., Maheshwari A. (eds) Uterine Cancer. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1892-0_33
26. Mailankody S, Bajpai J. Intelligent adaptation to the changing surroundings amidst the COVID-19 pandemic for sarcomas and melanomas. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Sep 27];3, Suppl S1:110-4. Available from: https://www.crstonline.com/text.asp?2020/3/5/110/283299
27. Bajpai J, Susan D. Adjuvant chemotherapy in soft tissue sarcomas…Conflicts, consensus, and controversies; SAJC South Asian Journal of Cancer January-March 2016 Volume 5 Issue 1
28. Khanna N, Pandey A, Bajpai J (corresponding author). Metastatic Ewing's Sarcoma: Revisiting the "Evidence on the Fence", with manuscript number Indian J Med Paediatr Oncol. 2017 Apr-Jun; 38(2): 173–181.doi: 4103/ijmpo.ijmpo_24_17
29. Ghosh J, Bajpai J (corresponding author) Chemotherapy for osteosarcoma: Adverse effects and remedial measures. Pediatric Hematology Oncology Journal xxx2017 1e7.
30. Bajpai J, Patel S. Sarcomas: Difficult to tame tumors! South Asian J Cancer 2016; 5: Issue 3,137-8.
31. Bajpai J et.al: A case report of Osteogenicsarcoma with Leprosy Journal of Cancer Research and Therapeutics. 2013; 9:311-3

 f) Immuno-oncology

1. Abraham G et al. (Bajpai J- corresponding author)."The clinical utility and safety of Short Course Immune check point inhibitors (ICI) in multiple tumors - A real world multicentric study from India". International Journal of Cancer. Int J Cancer. 2022 Mar 15;150(6):1045-1052. doi: 10.1002/ijc.33868. Epub 2021 Nov 25. PMID: 34751432.
2. Srinivas S, Bajpai J. Immunotherapy in special and rare situations: a brief review. J Immunother Precis Oncol. Published online. DOI: 10.36401/JIPO-21-6.
3. Bajpai J. Cancer Immunotherapy for immuno compromised Patients: An Often Ignored, yet Vital Puzzle. Journal of Immunotherapy and Precision Oncology (2020)3 (1): 1–2https://doi.org/10.4103/2666-2345.278414

g) Other Rare cancers –Melanoma, Schwanoma

1. Bajpai J et.al. Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas - Experience from a Tertiary Cancer Centre in India. Oncol, 08 September 2021 https://doi.org/10.3389/fonc.2021.710585
2. Bajpai J, Kapoor A, Jalali R,Gounder M. Checkpoint inhibitors and radiotherapy in refractory malignant melanocytic schwannoma with Carney complex: first evidence of efficacy BMJ Case Rep 2021;14: e240296. doi:10.1136/bcr-2020- 240296
3. Sahay A.,EpariS., GuptaP. … Bajpai J. et al. Melanotic Schwannoma, a Deceptive Misnomer for a Tumor with Relative Aggressive Behavior: A Series of 7 Cranial and Spinal Cases. International Journal of Surgical Pathology. 2020; 28 (8): 850-858 doi:10 . 1177 /1066896920923146.

International Guideline Articles

1. Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer Set al. ESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: clinicalguidelines@esmo.org. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021 Jul 22: S0923-7534(21)02184-0. doi: 10.1016/j.annonc.2021.07.006. Epub ahead of print. PMID: 34303806.
2. Strauss SJ, Frezza AM, Abecassis N, Bajpai J, Bauer S, Biagini R et al. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN Paed Can Clinical Practice Guideline for diagnosis, treatment and follow-up bone sarcomas. Ann Oncol.2021 Dec;32(12):1520-1536. doi: 10.1016/j.annonc.2021.08.1995. Epub 2021 Sep 6.
3. Casali P G, Blay JY, Abecassis N, Bajpai J, Bauer6, R. Biagini, et al. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS ClinicalPractice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022 Jan;33(1):20-33. doi: 10.1016/j.annonc.2021.09.005. Epub 2021 Sep 21. PMID: 34560242
4. Disis M, Adams SF, Bajpai J et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer. The Journal for Immunotherapy of Cancer (JITC)(in press)

International Consensus /Position papers

1. Stacchiotti S., Miah B., Frezza1 M., Messiou, Morosi, Caraceni A., Antonescu R., Bajpai J, et al. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. Https://doi.org/10.1016/j.esmoop.2021.100170 volume 6 - issue 3 – 2021
2. Sacchiotti , Frezza A. M., Demetri G. D., BlayJ. Y. , Bajpai  J., BaldietG. G. al. Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. Cancer Treat Rev.. 2022 Aug 18; 110:102455. doi: 10.1016/j.ctrv.2022.102455.
3. Stacchiotti S., DürrHans R., Schaefer I.-M., Woertler K.,HaasR.,.TramaA, CaraceniA., Bajpai J. et al. Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts. Cancer Treatment Reviews,Volume112, 2023, 102491, ISSN030572, https://doi.org/10.1016/j.ctrv.2022.(https://www.sciencedirect.com/science/article/pii/S0305737222001608)

National Guidelines

1. Bajpai J et al. ISMPO Young Breast cancer and oncofertilty guidelines –in press
2. Bajpai J et al. Melanoma guidelines –under consideration
3. Chopra S J…Bajpai J, Shrivastava SK. National Cancer Grid of India Consensus Guidelines on the Management of Cervical Cancer.J Glob Oncol.2018 Jul;(4):1-15. doi: 10.1200/JGO.17.00152.

1. Bajpai J et.al."Randomized controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia". Breast. 2019 Dec 12; 49:187-193. doi: 10.1016/j.breast.2019.12.004.
2. Bajpai J et.al. Osteosarcoma journey over two decades in India: Small steps, big changes; Pediatr Blood Cancer. 2019; e27877. https://doi.org/10.1002/pbc.27877
3. Bajpai J et.al. Outcomes in Treatment-Naïve Patients with Metastatic Extremity Osteosarcoma Treated with OGS-12, a Novel Non–High-Dose Methotrexate–Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center; Journal of Global Oncology.2018. (4):1-10.
4. Bajpai , Panda G. S.,Chandrasekharan A., et.al. Adolescent–adult non metastatic Ewing sarcoma—Experience from a large developing country; Paediatric Blood and Cancer Journal; Volume68, Issue9, September 2021, e29081; 15 May 2021; https://doi.org/10.1002/pbc.29081.

Immuno-oncology: Pioneered Immuno-oncology Society of India to increase awareness and enhance knowledge and access of ICI in country

1. Abraham G et al. (Bajpai J- corresponding author)."The clinical utility and safety of Short Course Immune check point inhibitors (ICI) in multiple tumors - A real world multicentre study from India". International Journal of Cancer. Int J Cancer. 2022 Mar 15;150(6):1045-1052. doi: 10.1002/ijc.33868. Epub 2021 Nov 25. PMID: 34751432.

Precision Care via dedicated Clinics

Melanoma Clinic: 

• Bajpai J et.al. Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas - Experience from a Tertiary Cancer Centre in India. Oncol, 08 September 2021 https://doi.org/10.3389/fonc.2021.710585

Adolescent and Young Adult Clinic

Mailankody S, Bajpai J(co-first and corresponding author) et al. Oncofertility and Pregnancy in Adolescent and Young Adult Cancers: Physicians' Knowledge and Preferences in India. JCO Glob Oncol. 2024;10:e2300205. doi:10.1200/GO.23.00205

Global AYA cancers California-2023

Breakout session: Chair: “Bridging the Divide: Care Patterns and Focus Areas for Adolescents and Young Adults (AYA)

Oral presentations –2023

• Living with Osteosarcoma for Indian Adolescents and Young Adults (AYA)–Is The World Listening?
• Clinical Profile and Outcomes of Metastatic Breast cancer in young women (m-YBC) (<40 years age): Real World Data from India.
• Outcomes of Adolescents and Young Adults with Metastatic Osteosarcoma in a Tertiary Care Cancer Centre in India Connective Tissue Oncology Society (CTOS) 2022-Vancouer, Canada. Best Poster award: AYA Category.
  Outcomes, prognostic factors and treatment compliance in Osteosarcoma cases treated with an indigenous, low-cost protocol, ogs-12, in a tertiary care cancer centre in India. abstract id: 1301438

• Bajpai J et.al. "Unique Challenges and Outcomes of Young Breast Cancers from a Tertiary Care Cancer Centre in India. Breast. 2021 Dec;60:177-184. doi: 10.1016/j.breast.2021.09.008. Epub 2021 Oct 6.
• Bajpai J et.al. Pregnancy associated breast cancer (PABC): Report from a gestational cancer registry from a tertiary cancer care centre, India. The Breast. Volume, April 2021, Pages 88-95

Precision Oncology

• Collaboration with MSKCC and India wide oncologist for pathway specific care and education

Low cost sustainable Care for all:

Evolution of Osteosarcoma care In institution with development of Low cost easy to administer, outpatient based “OGS-12” protocol with internationally comparable results and adopted in prestigious international guidelines (ESMO, ARIA)

1. Bajpai Jal. Osteosarcoma journey over two decades in India: Small steps, big changes; Pediatr Blood Cancer. 2019; e27877. https://doi.org/10.1002/pbc.27877
2. Bajpai Jal. Outcomes in Treatment-Naïve Patients with Metastatic Extremity Osteosarcoma Treated with OGS-12, a Novel Non–High-Dose Methotrexate–Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center; Journal of Global Oncology.2018. (4):1-10.

Mitigating Chemotherapy toxicity &Challenging Supportive care dogmas  in randomized fashion 

1. Bajpai J et.al."Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia". Breast. 2019 Dec 12; 49:187-193. doi: 10.1016/j.breast.2019.12.004.

Potentially Practice Changing Randomized Projects 

1. A randomized, open label phase III trial Evaluating Low-Dose Vs standard- dose  Olanzapine with standard triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy induced Nausea and vomiting in subjects with osteosarcoma and other solid tumors (OLAnzaPiNE) at TMH (completed)
2. Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia. (completed)
3. Acupuncture as a modality of treatment for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer-A Phase 3 Randomized Controlled Trial (ABC-CIPN) (completed)
4. A Double Blind Randomized Controlled Trial of Renal Protective Effects of Normal Saline Plus Placebo Versus Normal Saline Plus Mannitol Prior to Cisplatin Containing Chemotherapy Regimens in Osteosarcoma and other Solid Tumors (CiNeMa) (ongoing)

Establishing Care in difficult to treat cancers and situations

1. Bajpai J et.al. Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas - Experience from a Tertiary Cancer Centre in India. Oncol, 08 September 2021 https://doi.org/10.3389/fonc.2021.710585
2. Bajpai J et.al. "Unique Challenges and Outcomes of Young Breast Cancers from a Tertiary Care Cancer Centre in India. Breast. 2021 Dec; 60:177-184. doi: 10.1016/j.breast.2021.09.008. Epub 2021 Oct 6.
3. Bajpai J et.al. Pregnancy associated breast cancer (PABC): Report from a gestational cancer registry from a tertiary cancer care centre, India. The Breast. Volume, April 2021, Pages 88-95

Studying Quality of life of patients on chemotherapy: 

1. Bajpai J, Translation and Validation of EORTC QLQ-OV28 module into Indian languages (Hindi and Marathi) to study Quality of Life of Ca ovary patients from a tertiary care cancer centre, with manuscript number. South Asian Journal of Cancer.
2. Bajpai J, Panda PK, Kagwade S, et al. Translation and validation of European Organization for Research and Treatment for Cancer quality of life questionnaireOV-28 module into Indian languages (Hindi and Marathi) to study quality of life of ovarian cancer patients from a tertiary care cancer center. South Asian J Cancer 2018; 7:37-41

Ongoing randomized Projects 

1. A Double Blind Randomized Controlled Trial of Renal Protective Effects of Normal Saline Plus Placebo Versus Normal Saline Plus Mannitol Prior to Cisplatin Containing Chemotherapy Regimens in Osteosarcoma and other Solid Tumors (CiNeMa) (ongoing)
2. Acupuncture as a modality of treatment for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer-A Phase 3 Randomized Controlled Trial (ABC-CIPN) (ongoing)

Contribution towards Patient awareness booklets:

1. Early Breast cancer
2. Metastatic breast cancer
3. Exercise lymphedema
4. Breast reconstruction
5. Coping with hair loss
6. Cervical cancer
7. Immuno therapy

Trial Participation (PI/Co-PI):

Contributing towards many major international and national trials at Tata Memorial Cancer Center.

Trial Details: